Adult height in XXXX with central precocious puberty treated with @entity4396 agonist with or without @entity2124 .

@entity1 @entity4396 @entity4479 @entity4397 @entity2124 @entity7541 @entity2556 @entity214
PURPOSE: There is controversy surrounding the growth outcomes of treatment with @entity4396 agonist ( @entity4397 ) in central precocious puberty (CPP). We analyzed height preservation after treatment with @entity4397 with and without @entity2124 ( @entity2124 ) in @entity1 with CPP. METHODS: We reviewed the medical records of 82 @entity1 with idiopathic CPP who had been treated with @entity4397 at Severance @entity1 's Hospital from 2004 to 2014. We assessed the changes in height standard deviation score ( @entity214 ) for bone age (BA), and compared @entity4479 ( @entity4479 ) with midparental height ( @entity7541 ) and predicted @entity4479 ( @entity2556 ) during treatment in groups received @entity4397 alone (n=59) or @entity4397 plus @entity2124 (n=23). RESULTS: In the @entity4397 alone group, the height SDS for BA was increased during treatment. @entity4479 (160.4  4.23 cm) was significantly higher than the initial @entity2556 (156.6  3.96 cm) (P<0.001), and it was similar to the @entity7541 (159.9  3.52 cm). In the @entity4397 plus @entity2124 group, the height SDS for BA was also increased during treatment. @entity4479 (159.3  5.33 cm) was also higher than the initial @entity2556 (154.6  2.55 cm) (P<0.001), which was similar to the @entity7541 (158.1  3.31 cm). Height gain was slightly higher than that in the @entity4397 alone group, however it statistically showed no significant correlation with @entity2124 treatment. CONCLUSION: In CPP @entity1 treated with @entity4397 , the height SDS for BA was increased, and the @entity4479 was higher than the initial @entity2556 . Combined @entity2124 treatment showed a limited increase in height gain.
